CompletedPhase 3NCT00650091
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Duke University
- Principal Investigator
- Marvin I Schwarz, MDUniversity of Colorado, Denver
- Intervention
- N-acetylcysteine (NAC)(drug)
- Enrollment
- 264 target
- Eligibility
- 35-85 years · All sexes
- Timeline
- 2009 – 2014
Study locations (26)
- University of Alabama - Birmingham, Birmingham, Alabama, United States
- University of California - Los Angeles, Los Angeles, California, United States
- University of California - San Francisco, San Francisco, California, United States
- National Jewish Medical and Research Center, Denver, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- University of Louisville, Louisville, Kentucky, United States
- Tulane University, New Orleans, Louisiana, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- St. Luke's Hospital, Chesterfield, Missouri, United States
- Weill Medical College of Cornell University, New York, New York, United States
- +11 more locations on ClinicalTrials.gov
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00650091 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics